This is the
talk page for discussing improvements to the
Covaxin article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
The
contentious topics procedure applies to this page. This page is related to
COVID-19, broadly construed, which has been
designated as a contentious topic. Editors who repeatedly or seriously fail to adhere to the purpose of Wikipedia, any expected standards of behaviour, or any normal editorial process may be blocked or restricted by an administrator. Editors are advised to familiarise themselves with the contentious topics procedures before editing this page. |
This article is written in Indian English, which has its own spelling conventions (colour, travelled, centre, analysed, defence) and some terms that are used in it may be different or absent from other varieties of English. According to the relevant style guide, this should not be changed without broad consensus. |
This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||||||||||||
|
It is requested that a biochemistry diagram or diagrams be
included in this article to
improve its quality. Specific illustrations, plots or diagrams can be requested at the
Graphic Lab. For more information, refer to discussion on this page and/or the listing at Wikipedia:Requested images. |
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Covaxin.
|
The result of the move request was: page moved. Murtaza.aliakbar ( talk) 09:23, 16 May 2021 (UTC)
BBV152 →
Covaxin – As per
WP:COMMONNAME. Bharat Biotech, the developing company markets it as COVAXIN. They are developing another vaccine, but that's not named commercially, so it's BBV154 only. Whereas, COVAXIN case is the opposite,
bharatbiotech.com
Saha ❯❯❯ Stay safe
18:08, 9 May 2021 (UTC)
The following Wikimedia Commons file used on this page or its Wikidata item has been nominated for deletion:
Participate in the deletion discussion at the nomination page. — Community Tech bot ( talk) 07:02, 30 June 2021 (UTC)
This
edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
The efficacy section is unclear, as it does not clearly specify the overall efficacy of the vaccine.
Please add to the section:
The overall efficacy of Covaxin in 77.8%.
Sources: https://timesofindia.indiatimes.com/india/covaxins-overall-efficacy-77-8-65-2-effective-against-delta-variant-bharat-biotech/articleshow/84087789.cms https://www.gavi.org/vaccineswork/indias-covaxin-vaccine-shows-high-efficacy-against-covid-19-infections-phase-3 Dhruv Malik ( talk) 08:07, 16 July 2021 (UTC)
It should be mentioned in quite beginning of this article that this is a 2-dose vaccine.
-- ee1518 ( talk) 16:38, 4 September 2021 (UTC)
This
edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
Please replace the phase-III preprint reference with this peer reviewed article [1] at the Covaxin#Efficacy and Covaxin#Phase_III_trials sections.
References
2402:3A80:6CF:BBB9:CD3F:2714:94D5:8EC5 ( talk) 10:36, 12 November 2021 (UTC)
9165090187 — Preceding unsigned comment added by 2409:4043:4C81:3D22:7021:FEB3:28BD:F663 ( talk) 13:35, 22 February 2022 (UTC)